Naturally attenuated HIV--lessons for AIDS vaccines and treatment

Editorial

. 1999 Jun 3;340(22):1756-7.

doi: 10.1056/NEJM199906033402210.

Editorial

K L Collins et al. N Engl J Med. 1999.

. 1999 Jun 3;340(22):1756-7.

doi: 10.1056/NEJM199906033402210.

No abstract available

Comment on

Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort.
Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia RJ, Dyer WB, McIntyre L, Oelrichs RB, Rhodes DI, Deacon NJ, Sullivan JS. Learmont JC, et al. N Engl J Med. 1999 Jun 3;340(22):1715-22. doi: 10.1056/NEJM199906033402203. N Engl J Med. 1999. PMID: 10352163

Attenuated HIV vaccine: caveats.
Ruprecht RM, Baba TW, Liska V. Ruprecht RM, et al. Science. 1996 Mar 29;271(5257):1790-2. Science. 1996. PMID: 8596941 No abstract available.
[HIV eradication--facts and fiction].
Jaeger H, Wolf E. Jaeger H, et al. MMW Fortschr Med. 2008 Apr 28;150 Spec No 1:72-3. MMW Fortschr Med. 2008. PMID: 19024923 German. No abstract available.
Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort.
Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia RJ, Dyer WB, McIntyre L, Oelrichs RB, Rhodes DI, Deacon NJ, Sullivan JS. Learmont JC, et al. N Engl J Med. 1999 Jun 3;340(22):1715-22. doi: 10.1056/NEJM199906033402203. N Engl J Med. 1999. PMID: 10352163
Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity.
Kent SJ, Fernandez CS, Dale CJ, Davenport MP. Kent SJ, et al. Trends Microbiol. 2005 Jun;13(6):243-6. doi: 10.1016/j.tim.2005.03.011. Trends Microbiol. 2005. PMID: 15936652 Review.
Genetic diversity of HIV-1: the moving target.
Peeters M, Sharp PM. Peeters M, et al. AIDS. 2000;14 Suppl 3:S129-40. AIDS. 2000. PMID: 11086856 Review. No abstract available.